Loxoprofen-SRS is a non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (IC50s = 0.5 and 0.39 for recombinant human COX-1 and COX-2, respectively) and an active metabolite of the prodrug loxoprofen .[1] Intravenous administration of loxoprofen-SRS inhibits acetic acid-induced writhing, reduces carrageenan-induced mechanical hyperalgesia, and decreases carrageenan-induced paw edema in rats (ED50s = 0.43, 1.28, and 8.01 mg/kg, respectively).[2]
References:
[1].Riendeau, D., Salem, M., Styhler, A., et al.Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2Bioorg. Med. Chem. Lett.14(5)1201-1203(2004).
[2].Ye, H., Lv, T., Min, T., et al.HR1405-01, a safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trialsEur. J. Med. Chem.235:114258(2022).